Stay updated on Nivolumab and Tumor Infiltrating Lymphocytes Clinical Trial

Sign up to get notified when there's something new on the Nivolumab and Tumor Infiltrating Lymphocytes Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab and Tumor Infiltrating Lymphocytes Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    The page now displays the ClinicalTrials.gov record for the completed phase 1 nivolumab and tumor-infiltrating lymphocyte study, including its study details, eligibility criteria, and outcomes, instead of a 403 error.
    Difference
    61%
    Check dated 2026-11-08T13:45:58.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.2 to v3.8.0; the study record is still unavailable behind a 403 Forbidden page.
    Difference
    0.2%
    Check dated 2026-11-01T15:02:47.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    A site-wide banner announces an NIH terminology transition, noting that “Super Intelligence” (SI) is replacing “Artificial Intelligence” (AI) in some NIH content.
    Difference
    1%
    Check dated 2026-10-25T13:56:19.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision changed from v3.7.1 to v3.7.2, while the study record continues to display a 403 error.
    Difference
    0.2%
    Check dated 2026-10-18T14:34:41.000Z thumbnail image
  6. Check
    36 days ago
    Change Detected
    Summary
    The footer’s site revision identifier changes from v3.7.0 to v3.7.1 on the 403 error page.
    Difference
    0.2%
    Check dated 2026-10-11T14:07:34.000Z thumbnail image
  7. Check
    57 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error, replacing the expected study details and indicating access restrictions or a site issue.
    Difference
    20%
    Check dated 2026-09-20T20:09:56.000Z thumbnail image

Stay in the know with updates to Nivolumab and Tumor Infiltrating Lymphocytes Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab and Tumor Infiltrating Lymphocytes Clinical Trial page.